Rare endocrine and obesity drug acquisitions hit $12.9B; new MC4R therapies show promise but face tolerability challenges.

Neurocrine starts Phase 1 trial for new obesity drug NBIP-'1968 targeting multiple metabolic pathways.

Neurocrine Biosciences has initiated a Phase 1 clinical trial to test the safety and tolerability of NBIP-'1968, a novel triple agonist drug targeting GLP-1, GIP, and glucagon receptors for obesity treatment. This investigational drug aims to address...